196 related articles for article (PubMed ID: 10716235)
1. Protection of neonatal rat brain from hypoxic-ischemic injury by LY379268, a Group II metabotropic glutamate receptor agonist.
Cai Z; Xiao F; Fratkin JD; Rhodes PG
Neuroreport; 1999 Dec; 10(18):3927-31. PubMed ID: 10716235
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effects of N-acetylaspartylglutamate in a neonatal rat model of hypoxia-ischemia.
Cai Z; Lin S; Rhodes PG
Eur J Pharmacol; 2002 Feb; 437(3):139-45. PubMed ID: 11890901
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo.
Bond A; Jones NM; Hicks CA; Whiffin GM; Ward MA; O'Neill MF; Kingston AE; Monn JA; Ornstein PL; Schoepp DD; Lodge D; O'Neill MJ
J Pharmacol Exp Ther; 2000 Sep; 294(3):800-9. PubMed ID: 10945827
[TBL] [Abstract][Full Text] [Related]
4. Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain.
Di Liberto V; Bonomo A; Frinchi M; Belluardo N; Mudò G
Neuroscience; 2010 Feb; 165(3):863-73. PubMed ID: 19909793
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment with mGluR2 or mGluR3 Agonists Reduces Apoptosis Induced by Hypoxia-Ischemia in Neonatal Rat Brains.
Bratek-Gerej E; Bronisz A; Ziembowicz A; Salinska E
Oxid Med Cell Longev; 2021; 2021():8848015. PubMed ID: 33763176
[TBL] [Abstract][Full Text] [Related]
6. Group II Metabotropic Glutamate Receptors Reduce Apoptosis and Regulate BDNF and GDNF Levels in Hypoxic-Ischemic Injury in Neonatal Rats.
Bratek-Gerej E; Ziembowicz A; Salinska E
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806000
[TBL] [Abstract][Full Text] [Related]
7. LY379268, a potent and selective Group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia.
Bond A; Ragumoorthy N; Monn JA; Hicks CA; Ward MA; Lodge D; O'Neill MJ
Neurosci Lett; 1999 Oct; 273(3):191-4. PubMed ID: 10515191
[TBL] [Abstract][Full Text] [Related]
8. Amyloid-beta neurotoxicity and clearance are both regulated by glial group II metabotropic glutamate receptors.
Durand D; Carniglia L; Turati J; Ramírez D; Saba J; Caruso C; Lasaga M
Neuropharmacology; 2017 Sep; 123():274-286. PubMed ID: 28495373
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of LY379268, a selective group II metabotropic glutamate receptor agonist, on dizocilpine-induced neuropathological changes in rat retrosplenial cortex.
Okamura N; Hashimoto K; Shimizu E; Koike K; Ohgake S; Koizumi H; Kumakiri C; Komatsu N; Iyo M
Brain Res; 2003 Nov; 992(1):114-9. PubMed ID: 14604779
[TBL] [Abstract][Full Text] [Related]
10. Effects of LY379268, a selective group II metabotropic glutamate receptor agonist on EEG activity, cortical perfusion, tissue damage, and cortical glutamate, glucose, and lactate levels in brain-injured rats.
Stover JF; Sakowitz OW; Beyer TF; Dohse NK; Kroppenstedt SN; Thomale UW; Schaser KD; Unterberg AW
J Neurotrauma; 2003 Apr; 20(4):315-26. PubMed ID: 12866811
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effect of the peptides ADNF-9 and NAP on hypoxic-ischemic brain injury in neonatal rats.
Kumral A; Yesilirmak DC; Sonmez U; Baskin H; Tugyan K; Yilmaz O; Genc S; Gokmen N; Genc K; Duman N; Ozkan H
Brain Res; 2006 Oct; 1115(1):169-78. PubMed ID: 16938277
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotection by metabotropic glutamate receptor glutamate receptor agonists: LY354740, LY379268 and LY389795.
Kingston AE; O'Neill MJ; Lam A; Bales KR; Monn JA; Schoepp DD
Eur J Pharmacol; 1999 Jul; 377(2-3):155-65. PubMed ID: 10456425
[TBL] [Abstract][Full Text] [Related]
13. Tolerance to the motor impairment, but not to the reversal of PCP-induced motor activities by oral administration of the mGlu2/3 receptor agonist, LY379268.
Cartmell J; Monn JA; Schoepp DD
Naunyn Schmiedebergs Arch Pharmacol; 2000 Jan; 361(1):39-46. PubMed ID: 10651145
[TBL] [Abstract][Full Text] [Related]
14. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268.
Lorrain DS; Baccei CS; Bristow LJ; Anderson JJ; Varney MA
Neuroscience; 2003; 117(3):697-706. PubMed ID: 12617973
[TBL] [Abstract][Full Text] [Related]
15. Effects of the selective metabotropic glutamate agonist LY354740 in a rat model of permanent ischaemia.
Lam AG; Soriano MA; Monn JA; Schoepp DD; Lodge D; McCulloch J
Neurosci Lett; 1998 Sep; 254(2):121-3. PubMed ID: 9779935
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective potential of group I metabotropic glutamate receptor antagonists in two ischemic models.
Makarewicz D; Duszczyk M; Gadamski R; Danysz W; Łazarewicz JW
Neurochem Int; 2006; 48(6-7):485-90. PubMed ID: 16513218
[TBL] [Abstract][Full Text] [Related]
17. Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateral sclerosis.
Battaglia G; Riozzi B; Bucci D; Di Menna L; Molinaro G; Pallottino S; Nicoletti F; Bruno V
Neurobiol Dis; 2015 Feb; 74():126-36. PubMed ID: 25434487
[TBL] [Abstract][Full Text] [Related]
18. The metabotropic glutamate 2/3 receptor agonist LY379268 counteracted ketamine-and apomorphine-induced performance deficits in the object recognition task, but not object location task, in rats.
Pitsikas N; Markou A
Neuropharmacology; 2014 Oct; 85():27-35. PubMed ID: 24859609
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia.
Bond A; O'Neill MJ; Hicks CA; Monn JA; Lodge D
Neuroreport; 1998 Apr; 9(6):1191-3. PubMed ID: 9601692
[TBL] [Abstract][Full Text] [Related]
20. Hypothermia Is Neuroprotective after Severe Hypoxic-Ischaemic Brain Injury in Neonatal Rats Pre-Exposed to PAM3CSK4.
Falck M; Osredkar D; Maes E; Flatebø T; Wood TR; Walløe L; Sabir H; Thoresen M
Dev Neurosci; 2018; 40(3):189-197. PubMed ID: 29860252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
